eSymposia | Antibodies and Vaccines as Drugs for COVID-19

Jan 13, 2021 ‐ Jan 14, 2021


Sessions

Antibodies as Drugs for COVID‑19 iconAntibodies as Drugs for COVID‑19

Preview Available

Antibodies as Drugs for COVID‑19

Jan 13, 2021 9:00am ‐ Jan 13, 2021 11:40am

Co-Chair(s):
Combating COVID‑19: Identifying a Potential Drug Candidate for Human Testing in 90 Days iconCombating COVID‑19: Identifying a Potential Drug Candidate for Human Testing in 90 Days

Preview Available

Combating COVID‑19: Identifying a Potential Drug Candidate for Human Testing in 90 Days

Jan 13, 2021 9:00am ‐ Jan 13, 2021 9:15am

Speaker(s):
Rapid Selection, Characterization and Clinical Development of Fully‑Human Antibodies Against Emerging Infectious Diseases iconRapid Selection, Characterization and Clinical Development of Fully‑Human Antibodies Against Emerging Infectious Diseases

Preview Available

Rapid Selection, Characterization and Clinical Development of Fully‑Human Antibodies Against Emerging Infectious Diseases

Jan 13, 2021 9:15am ‐ Jan 13, 2021 9:30am

Speaker(s):
Cross‑Neutralization of SARS‑CoV‑2 by a Human Monoclonal SARS‑CoV Antibody iconCross‑Neutralization of SARS‑CoV‑2 by a Human Monoclonal SARS‑CoV Antibody

Preview Available

Cross‑Neutralization of SARS‑CoV‑2 by a Human Monoclonal SARS‑CoV Antibody

Jan 13, 2021 9:30am ‐ Jan 13, 2021 9:45am

Speaker(s):
Neutralizing Antibodies—The Hope for a COVID‑19 Cure iconNeutralizing Antibodies—The Hope for a COVID‑19 Cure

Preview Available

Neutralizing Antibodies—The Hope for a COVID‑19 Cure

Jan 13, 2021 9:45am ‐ Jan 13, 2021 10:00am

Speaker(s):
Coffee Break iconCoffee Break

Preview Available

Coffee Break

Jan 13, 2021 10:00am ‐ Jan 13, 2021 10:25am

Human Neutralizing Antibodies Elicited by SARS‑CoV‑2 Infection iconHuman Neutralizing Antibodies Elicited by SARS‑CoV‑2 Infection

Preview Available

Human Neutralizing Antibodies Elicited by SARS‑CoV‑2 Infection

Jan 13, 2021 10:25am ‐ Jan 13, 2021 10:40am

Speaker(s):
When Size Matters: A Broadly Neutralizing Single Domain Antibody to Prevent and Treat COVID 19 iconWhen Size Matters: A Broadly Neutralizing Single Domain Antibody to Prevent and Treat COVID 19

Preview Available

When Size Matters: A Broadly Neutralizing Single Domain Antibody to Prevent and Treat COVID 19

Jan 13, 2021 10:40am ‐ Jan 13, 2021 10:55am

Speaker(s):
Highly Potent Anti‑SARS‑CoV‑2 Multivalent DARP in Therapeutic Candidates iconHighly Potent Anti‑SARS‑CoV‑2 Multivalent DARP in Therapeutic Candidates

Preview Available

Highly Potent Anti‑SARS‑CoV‑2 Multivalent DARP in Therapeutic Candidates

Jan 13, 2021 10:55am ‐ Jan 13, 2021 11:10am

Speaker(s):
Therapeutic Effect of Regdanvimab (CT‑P59) in Patients with Mild to Moderate Symptoms of SARS CoV 2 Infection iconTherapeutic Effect of Regdanvimab (CT‑P59) in Patients with Mild to Moderate Symptoms of SARS CoV 2 Infection

Preview Available

Therapeutic Effect of Regdanvimab (CT‑P59) in Patients with Mild to Moderate Symptoms of SARS CoV 2 Infection

Jan 13, 2021 11:10am ‐ Jan 13, 2021 11:25am

Speaker(s):